Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634 1638
This examiner grants 30% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17607354 | BEAD-FREE EX-VIVO EXPANSION OF HUMAN REGULATORY T CELLS | Final Rejection | The Regents of the University of California |
| 16768462 | MAINTENANCE-AND-AMPLIFICATION METHOD AND DIFFERENTIATION INDUCTION METHOD FOR PRIMORDIAL GERM CELLS/PRIMORDIAL GERM CELL-LIKE CELLS | Final Rejection | KYOTO UNIVERSITY |
| 16929948 | High Specificity Genome Editing Using Chemically Modified Guide RNAs | Final Rejection | Agilent Technologies, Inc. |
| 17762313 | PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | Final Rejection | A2 BIOTHERAPEUTICS, INC. |
| 17309451 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | Non-Final OA | Celularity Inc. |
| 17919144 | B CELL IMMUNOMODULATORY THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME | Final Rejection | Holy Cross Hospital, Inc. |
| 17781479 | IN VITRO AND IN VIVO GENE DELIVERY TO IMMUNE EFFECTOR CELLS USING NANOPARTICLES FUNCTIONALIZED WITH DESIGNED ANKYRIN REPEAT PROTEINS (DARPINS) | Final Rejection | BIONTECH CELL & GENE THERAPIES GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy